Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 10/20 | 0.77 |
| ▸ | AURKA | O14965 | 1/20 | 0.77 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.77 |
| ▸ | NEK2 | P51955 | 1/20 | 0.65 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.52 |
| ▸ | INSR | P06213 | 2/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25837707 | 0.91 | AXL (0.78) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL25837703 | 0.89 | AXL (0.74) | AXLAURKAAURKBNEK2PTK2 | |
| Dubermatinib SCHEMBL12813478 | 0.87 | AXL (1.00) | AXLAURKAAURKBNEK2PTK2 | |
| Dubermatinib SCHEMBL29394359 | 0.87 | AXL (1.00) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL25838209 | 0.86 | AXL (0.75) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL31173448 | 0.86 | AXL (0.75) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL21446913 | 0.85 | AXL (0.87) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL24727537 | 0.84 | AXL (0.86) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL21446896 | 0.84 | AXL (0.83) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL25838868 | 0.84 | AXL (0.53) | AXLAURKAAURKBPTK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4464699-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Lisen Therapeutics, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240360145-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | LISEN THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| WO-2023134582-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海立森印迹医药技术有限公司 | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360145-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | DPYD, TYMP, TYMS | AXL 868/4885AURKA 1088/4885AURKB 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.